Table 1.
The clinical and pathological characteristics of the 40 patients with postoperative brain metastasis from non-small cell lung cancer
| Gender (male/female) | 25/15 |
| Age (years) | 65.0 ± 8.9 (49–79) |
| Primary lesion | |
| Operation (Lobe/Bil-lobe or Pneumo) | 33/7 |
| Pathological stage (1a/1b/2a/2b/3a) | 7/6/10/9/8 |
| Histologic classification (Ad/Others ) | 24/16 |
| Adjuvant chemotherapy (Yes/No) | 20/20 |
| Brain lesion | |
| Interval to brain metastasis after surgery (months) | 10.2 ± 8.4 (2.1–32.3) |
| Number of brain meta (Single/Multiple) | 26/14 |
| Tumor size of brain metastasis (mm) | 21.5 ± 15.5 (5–70) |
| Radiotherapy† (Yes/No) | 14/26 |
| Radical treatment‡ (Yes/No) | 29/11 |
| Symptom before Tx (Yes/No) | 26/14 |
| CEA level at the time of recurrence (ng/ml) | 1.4–78.6 |
| Extracranial metastasis (Yes/No) | 17/23 |
| Chemotherapy after treatment for brain (Yes/No) | 12/28 |
| EGFR-TKI (Yes/No) | 7/33 |
†
SRS and/or WBRT. ‡2 SRS and/or Craniotomy. Ad, adenocarcinoma; CEA, carcinoembryonic antigen; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitors.